Malvern-based Neuronetics Recognized as 2020 Top Neurology Device Provider

Neuronetics, Inc
Company acknowledged on Top 10 List by MedTech Outlook Magazine

MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, this week announced it has been named a Top 10 Neurology Device Provider in 2020 by MedTech Outlook Magazine.

“The country’s COVID-19 crisis emphasizes how important it is, now more than ever, that we strive to improve the quality of life for those suffering from mental health conditions. We are honored to receive this recognition from such a reputable publication as it reflects the dedication, ambition and compassion we pour into our work every day,” said Dan Guthrie, Chief Commercial Officer of Neuronetics, Inc. “We hope this recognition will help to further increase awareness of NeuroStar as safe, non-drug treatment option that may help some of the millions of adults in the U.S. who are suffering from depression.”

READ:  FDA Approves New Therapy for Myelodysplastic Syndromes (MDS) That Can Be Taken at Home

Neuronetics was named to this listing by a distinguished selection panel — comprised of chief medical officers, medical directors, department heads, and the editorial board of MedTech Outlook — and joins an impressive group of companies that provide innovative, transformative technologies and devices.

Since receiving FDA clearance in 2008 to treat Major Depressive Disorder (MDD) in adult patients, Neuronetics’ commercial product, a transcranial magnetic stimulation (TMS) device called NeuroStar® Advanced Therapy, has delivered over 2.8 million treatments to patients suffering from depression and is the number one TMS choice of doctors. The non-drug, non-invasive treatment uses magnetic pulses to stimulate areas of the brain that are underactive in depression. In an open-label clinical trial, 58 percent of patients responded to treatment and 37 percent experienced complete remission from depression. Treatment sessions can be performed in as little as 19 minutes* and it is covered by most major insurance providers, making it available and accessible to a growing patient population.

READ:  Annovis Bio Receives Institutional Review Board Approval to Initiate Phase 2 Study

In addition to making MedTech Outlook’s listing as a top device provider, Neuronetics continues to drive important change in the industry by transforming the neurohealth space through global expansion and setting the stage for future treatment indications.

To see the complete list of the Top 10 Neurology Device Providers of 2020, visit MedTech Outlook here. For more information about Neuronetics, visit www.neuronetics.com.

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee